Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Co-Diagnostics (CODX): Exploring Opportunities in Portable PCR Diagnostics

Co-Diagnostics (CODX): Exploring Opportunities in Portable PCR Diagnostics

Key Takeaways

  • Co-Diagnostics, Inc. (CODX) is a U.S.-listed molecular diagnostics company that develops tests based on the detection and analysis of nucleic acids (DNA or RNA).
  • The company's flagship initiative is the Co-Dx PCR platform, a portable polymerase chain reaction (PCR) testing system designed for point-of-care and at-home use.
  • Its test pipeline spans infectious diseases such as tuberculosis, influenza, RSV, COVID-19, and human papillomavirus (HPV), among others.
  • Co-Diagnostics operates through joint ventures, notably CoSara in India and CoMira in Saudi Arabia and the wider MENA region, to localize manufacturing and distribution.
  • As a development-stage business, the company has generated limited revenue in recent years and has reported operating losses, a key consideration for investors.

Introduction

Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company designs, develops, and seeks to commercialize tests that detect and analyze genetic material, positioning itself to make sophisticated molecular testing faster, cheaper, and more accessible than traditional centralized laboratory methods. Investors follow the stock for its proprietary PCR technology, its point-of-care ambitions, and its efforts to build a global commercial footprint in emerging markets. From what I see, the focus on decentralization stands out as a core differentiator in this space.

Company Background and History

Co-Diagnostics was founded in 2013 by Dr. Brent C. Satterfield and Dwight H. Egan, who has served as its chief executive officer. The company completed its initial public offering (IPO) and began trading on the NASDAQ in July 2017. Its founding premise was a proprietary approach to PCR test design, including algorithms and reagents aimed at reducing costs and improving accuracy compared with competing PCR systems. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

PCR, or polymerase chain reaction, is a laboratory technique used to amplify small amounts of DNA or RNA so that a specific target — such as a virus or bacterium — can be detected. Co-Diagnostics' early intellectual property centered on mathematical algorithms for designing tests and a technique known as "Co-Primers," intended to reduce false-positive and false-negative results.

Business Model and Core Products

Co-Diagnostics' business model combines reagent and test sales with a broader platform strategy. Its primary focus is the Co-Dx PCR platform, an integrated system that includes the Co-Dx PCR Pro instrument, a proprietary disposable test cup, and a mobile application. The system is designed to bring PCR testing out of central laboratories and into point-of-care and at-home settings.

The company's pipeline includes tests for respiratory conditions (such as influenza A/B, RSV, and COVID-19), tuberculosis (TB), and HPV, as well as assays for other infectious diseases. Beyond infectious disease testing, Co-Diagnostics has also explored applications in agricultural genetics and other non-medical genetic-marker detection. Historically, the company's revenue has come primarily from diagnostic kits and equipment, supplemented by grant funding from organizations such as the Bill & Melinda Gates Foundation and the U.S. National Institutes of Health. During the COVID-19 pandemic, demand for its tests drove a significant revenue spike; in subsequent years, revenue declined sharply as pandemic-related demand faded.

Market Position and International Strategy

Co-Diagnostics competes in the molecular diagnostics market against larger, well-capitalized players, but it differentiates itself through a lower-cost, decentralized testing model. A central element of its strategy is international expansion through joint ventures. Through CoSara, its joint venture in India, the company has pursued regulatory clearances and local manufacturing for its PCR instruments and tests, with a particular emphasis on tuberculosis — a disease for which India represents one of the world's largest testing markets. Through CoMira, a joint venture with a local partner in Saudi Arabia, Co-Diagnostics aims to establish domestic molecular diagnostics manufacturing and distribution across the broader Middle East and North Africa (MENA) region.

Why Investors Follow CODX

Co-Diagnostics attracts investor attention primarily for its long-term growth potential rather than its current financial profile. The company's proprietary PCR technology and its push to enable decentralized, point-of-care testing address a genuine market need for faster and more affordable diagnostics, particularly in resource-limited settings. Its alignment with World Health Organization (WHO) guidance favoring near point-of-care molecular tuberculosis testing supports the relevance of its TB program. Its joint-venture model offers a capital-efficient route to local manufacturing and distribution in high-growth markets. Investors also monitor the company's regulatory progress, including FDA submissions for its respiratory tests, and its evolving use of artificial intelligence in assay design and data analysis.

Risks and Important Considerations

Co-Diagnostics carries the risk profile typical of a development-stage healthcare company. Its revenue base has been small in recent years, and the company has reported recurring operating losses as it invests in research, clinical studies, and manufacturing ahead of broad commercialization. Management has stated that additional capital may be required to fund its plans, and financing activity can dilute existing shareholders. The company's flagship Co-Dx PCR platform and its associated tests are subject to regulatory review by the FDA and other authorities and are not yet broadly available for sale in the United States. Regulatory timelines can shift, and approval is not guaranteed. The business also faces competition from larger diagnostics firms, exposure to evolving reimbursement and regulatory environments, and the risk that commercialization in emerging markets proceeds more slowly than anticipated.

Conclusion

Co-Diagnostics, Inc. is a molecular diagnostics company built around a proprietary PCR platform intended to make sophisticated genetic testing more portable, affordable, and accessible. While its current financial profile reflects the early, investment-heavy phase of a development-stage business, its technology, regulatory pipeline, and joint-venture strategy in India and the MENA region give it a distinctive market position. For investors, the stock represents an opportunity to follow a company pursuing decentralized diagnostics in both developed and emerging markets — alongside the risks inherent in a pre-commercial, capital-intensive business model.

AI Screener

In my own workflow, I frequently use Tickeron’s AI Screener to quickly compare companies like this one against peers based on fundamentals, trends, and patterns. It helps surface relevant ideas without sifting through endless data manually, and it has become a reliable part of how I evaluate development-stage names in diagnostics and beyond.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CODX

CODX in upward trend: price may jump up because it broke its lower Bollinger Band on October 14, 2026

CODX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 34 cases where CODX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CODX just turned positive on November 11, 2026. Looking at past instances where CODX's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CODX as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

CODX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CODX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CODX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.142). P/E Ratio (-0.010) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.171) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CODX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CODX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -6%. POAS experienced the highest price growth at 351%, while NPCE experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 24% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 60
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 13 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of molecular diagnostics products and tests that represents a radical new advancement in the understanding of the molecular interactions of DNA

Industry MedicalNursingServices

Industry
Biotechnology
Address
2401 S. Foothill Drive
Phone
+1 801 438-1036
Employees
115
Web
https://www.codiagnostics.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
LITE is the Nasdaq-listed ticker for Lumentum Holdings Inc., a global manufacturer of optical and photonic products used in data centers, AI infrastructure, and telecommunications networks. The company was spun off from JDS Uniphase and incorporated in 2015, with headquarters in San Jose, California.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SNDK is the NASDAQ ticker for SanDisk Corporation, a global developer and manufacturer of data storage products built on NAND flash memory technology. SanDisk is one of the world's largest suppliers of NAND flash semiconductors, offering solid-state drives (SSDs), embedded storage, removable memory cards, and USB flash drives.
QCOM is the ticker for Qualcomm Incorporated, a U.S.-based semiconductor and wireless technology company headquartered in San Diego, California. Qualcomm designs advanced chips and licenses foundational wireless patents, operating through two main segments: QCT (semiconductors) and QTL (technology licensing).